Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug–naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschueren, Patrick, De Cock, Diederik, Corluy, Luk, Joos, Rik, Langenaken, Christine, Taelman, Veerle, Raeman, Frank, Ravelingien, Isabelle, Vandevyvere, Klaas, Lenaerts, Jan, Geens, Elke, Geusens, Piet, Vanhoof, Johan, Durnez, Anne, Remans, Jan, Vander Cruyssen, Bert, Van Essche, Els, Sileghem, An, De Brabanter, Griet, Joly, Johan, Van der Elst, Kristien, Meyfroidt, Sabrina, Westhovens, Rene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422551/
https://www.ncbi.nlm.nih.gov/pubmed/25889222
http://dx.doi.org/10.1186/s13075-015-0611-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422551/
https://www.ncbi.nlm.nih.gov/pubmed/25889222
http://dx.doi.org/10.1186/s13075-015-0611-8

Ejemplares similares